About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT07146633

Efficacy of an EMDR App for PTSD and SUD

The current proposal is aimed to confirm the efficacy of this novel therapeutic method (autonomous eye movement desensitization and reprocessing; A-EMDR) in a patient group (PTSD and SUD), and to asse...

Lead sponsor: Centre for Addiction and Mental Health•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Centre for Addiction and Mental Health

This is an open-label pilot randomized, wait-list controlled trial evaluating A-EMDR for the treatment of PTSD in patients with SUD for four weeks with a follow up at week eight. Primary outcomes will be measured at the end of the study (week 4) for both groups and at follow up (week 8) for the A-EMDR group.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Aged 18-years old or older
•Fluent in English
•Diagnosed with PTSD by the PTSD Checklist for DSM-5 (PCL-5 past month version score \>32)
•Diagnosed with past-year substance use disorder other than caffeine by structured clinical interview for DSM-5 (SCID-5)
•Agrees not to participate in other treatments during the study duration (e.g., mindfulness, yoga, biofeedback, self-hypnosis or tai chi) except individuals who have been already on continuous therapies for at least three months

Exclusion Criteria

•Diagnosis of a severe or unstable mental illness that precludes safe participation in the study by a healthcare practitioner such as acute psychosis or mania diagnosed by a healthcare practitioner
•Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) (21) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes"

Related studies

Family Support Protocol for Adolescent Internalizing Disorders

NCT06413979 · Internalizing Disorders, Substance Use Disorders

IMPOWR-ME Project 1: Trial of Yoga and Physical Therapy Onsite at Opioid Treatment Programs

NCT05492825 · Substance Use Disorders, Chronic Pain, and more

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921 · Opioid-use Disorder, Substance Use Disorders

RECRUITINGPhase 4

Smoking Cessation and Menstrual Cycle Phase

NCT05515354 · Nicotine Dependence, Tobacco Smoking, and more

LHC-CIDI-5 in Hong Kong

NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 22, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment24

Start dateJan 2026

Last updatedMay 22, 2026

Condition

Posttraumatic Stress Disorder (PTSD)Substance Use Disorders

Locations shown

100 Stokes St

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 22, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions